A Phase 2 interventional study of Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch in Carpal Tunnel Syndrome, sponsored by ZARS Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.
Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing lidocaine in Carpal Tunnel Syndrome — 1 open to participants now, 1 under way, none of them phase 3. Lidocaine · Carpal Tunnel Syndrome.
Among the 10 studies testing lidocaine in Carpal Tunnel Syndrome, this one is the 10th largest by enrollment, is the only one that started in 2009, is the only one in phase 2, and was the 3rd registered.
589 studies on the registry are indexed under Carpal Tunnel Syndrome; 134 are open to participants now.
Browse Carpal Tunnel Syndrome studies →1 of the 10 studies testing lidocaine in Carpal Tunnel Syndrome is open now. Recruiting first, the newest first:
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 73 Carpal Tunnel Syndrome studies recruiting now, 27 (37%) set no upper age limit and 37 (51%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 60 across 444 interventional studies indexed under Carpal Tunnel Syndrome.
Median enrollment 51 across the 10 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 9 most frequent:
ZARS Pharma Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
ZARS Pharma Inc. has 1 study filed under Carpal Tunnel Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing lidocaine in Carpal Tunnel Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07283874Assiut UniversityDoes it Matter the Volume of Injectate on the Outcome of Ultrasound-guided Perineural Injection for Carpal Tunnel Syndrome | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing lidocaine in Carpal Tunnel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome.
ZARS Pharma, Inc. has developed Synera® (lidocaine 70 mg and tetracaine 70 mg topical patch), a drug delivery patch that utilizes controlled heat to enhance the delivery of a local anesthetic formulation consisting of a eutectic mixture of lidocaine and tetracaine. Synera was approved by the Food and Drug Administration (FDA) on June 23, 2005 and is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodesiccation, and shave biopsy of skin lesions.
The purpose of this single center, 2-week open-label pilot study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate CTS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Synera topical patch
Drug: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch
Drug page: Lidocaine
Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
Pain intensity
Time frame: Screening/Day 1, Day 8, and Day 15 or early withdrawal
Pain interference with activities (general, normal work, sleep)
Time frame: Screening/Day 1, Day 8, and Day 15 or early withdrawal
The record gives a start of Sep 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine